doi: 10.1210/endo-113-1-270
We now have a lower threshold to meet the U.S
Isaacs, D, Bellini N, Stahl-Salzman R
The primary endpoint in this trial, the difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 among PAXLOVID versus placebo recipients, was not met
To further expand the set of SpyLock-based bispecific formats for screening, it should also be possible to combine SpyLock with knob-in-hole Fc domains, with the caveat that exposed disulfides in the hinge region should either be avoided or, alternatively, reoxidized after bispecific generation 40
Weight management implications: If taking tirzepatide primarily for weight management, discuss how the temporary interruption may affect your progress and whether any additional support or dietary guidance is needed during the perioperative period